Association of Common C-Reactive Protein (CRP) Gene Polymorphisms With Baseline Plasma CRP Levels and Fenofibrate Response
The GOLDN Study
- Jian Shen, MD, PHD1,
- Donna K. Arnett, PHD2,
- Laurence D. Parnell, PHD1,
- James M. Peacock, PHD3,
- Chao-Qiang Lai, PHD1,
- James E. Hixson, PHD4,
- Michael Y. Tsai, MD, PHD5,
- Michael A. Province, PHD6,
- Robert J. Straka, PHD7 and
- Jose M. Ordovas, PHD1
- 1Nutrition and Genomics Laboratory, Jean Mayer–U.S. Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, Massachusetts
- 2Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama
- 3Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota
- 4Human Genetics Center, University of Texas, Houston, Texas
- 5Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota
- 6Division of Statistical Genomics, Washington University in Saint Louis, School of Medicine, Saint Louis, Missouri
- 7Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota
- Corresponding author: Jose M. Ordovas, PhD, Nutrition and Genomics Laboratory, Jean Mayer USDA HNRCA at Tufts University, 711 Washington St., Boston, MA 02111-1524. E-mail: jose.ordovas{at}tufts.edu
Abstract
OBJECTIVE—C-reactive protein (CRP) is an inflammatory marker that contributes to the prediction of cardiovascular disease. We investigated the influences of CRP polymorphisms on baseline CRP levels and fenofibrate-induced CRP changes in subjects with the metabolic syndrome.
RESEARCH DESIGN AND METHODS—We examined the association of CRP single nucleotide polymorphisms (SNPs) (m772A>G, m301G>A >T, i178T>A, 3u1273C>T, and 3u2131C>T) with baseline plasma CRP levels among 1,123 white U.S. participants in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Study and the modulating effect of these SNPs on CRP response to a 3-week fenofibrate treatment among 290 participants with the metabolic syndrome.
RESULTS—There were strong associations of m301G>A>T (rs3091244; P = 0.003), i178T>A (rs1417938; P = 0.001), 3u1273C>T (rs1130864; P = 0.001), and 3u2131C>T (rs1205; P < 0.001) with baseline CRP levels. Moreover, among subjects with the metabolic syndrome, fenofibrate induced the greatest reduction in CRP levels for TT subjects of the i178T>A compared with TA and AA subjects (−30 for TT, −19 for TA, and −11% for AA; P = 0.004). Similarly, for the m301G>A>T, major allele carriers displayed maximal reduction of CRP over noncarriers (−20 for GG, −15 for GA and GT, and −0.3% for TA and AA; P = 0.020).
CONCLUSIONS—Our results demonstrate that common genetic variants within the CRP gene affect baseline CRP levels and further modulate CRP response in subjects with the metabolic syndrome treated with fenofibrate. This knowledge could contribute to a better prediction of therapeutic success.
- CVD, cardiovascular disease
- CRP, C-reactive protein
- GOLDN, Genetics of Lipid Lowering Drugs and Diet Network
- LD, linkage disequilibrium
- PPAR-α, peroxisome proliferator–activated receptor α
- SNP, single nucleotide polymorphism
- USF1, upstream stimulating factor 1
Footnotes
-
Published ahead of print at http://care.diabetesjournals.org on 19 February 2008. DOI: 10.2337/dc07-1687.
Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/dc07-1687.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.
-
- Accepted February 10, 2008.
- Received August 26, 2007.
- DIABETES CARE
